Budigalimab

布格利单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameBudigalimab
Drug Alias NameABBV-181
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockersAnti-PD-1
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[22] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesAbbvie Pharmaceutical Trading（Shanghai）Co Ltd
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[16] 
Inactive IndicationsHead and Neck NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A